Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079339 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
A Phase 1 study of Untreated Childhood Brain Stem Glioma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT00079339 is a Phase 1 study of Untreated Childhood Brain Stem Glioma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00079339, a Phase 1 study of Untreated Childhood Brain Stem Glioma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may make tumor cells more sensitive to radiation therapy. Combining tipifarnib with radiation therapy may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of tipifarnib to see how well it works when given together with radiation therapy in treating young patients with newly diagnosed brain stem glioma. (Phase I closed to accrual as of 1/19/06)
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG tipifarnib
Study Locations (1)
Tennessee
- Pediatric Brain Tumor Consortium - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079339
The ClinicalTrials.gov registry entry for NCT00079339 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Untreated Childhood Brain Stem Glioma appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT00079339 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00079339 about?
NCT00079339 is a clinical study titled "Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma". Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may make tumor cells more sensitive to radiation therapy. Combining tipifarnib with radiation therapy may kill more tumor cell...
What is the current status of trial NCT00079339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2004-01. Estimated completion is 2009-11.
What conditions does trial NCT00079339 study?
This clinical trial studies the following conditions: Untreated Childhood Brain Stem Glioma.
What interventions are being tested in trial NCT00079339?
The interventions under investigation include: radiation therapy (RADIATION), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00079339?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00079339 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.